Skip to main content
. 2021 Sep 8;46(5):232. doi: 10.3892/or.2021.8183

Figure 3.

Figure 3.

NK cell-based immunotherapies. NK, natural killer; ADCC, antibody-dependent cell-mediated cytotoxicity; CAR, chimeric antigen receptor; EGFR, epidermal growth factor receptor; HSP, heat shock proteins; IL, interleukin; mAb, monoclonal antibody; NKG2A, natural killer group 2 member A; PD-1, programmed cell death-1; HLA, human leukocyte antigen.